Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.90
Bid: 4.80
Ask: 5.00
Change: 0.05 (1.03%)
Spread: 0.20 (4.167%)
Open: 4.85
High: 4.90
Low: 4.85
Prev. Close: 4.85
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

15 Feb 2013 13:59

RNS Number : 0141Y
Eden Research plc
15 February 2013
 



 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Eden Research

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

 

 

YES

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation: iii

J. M. FINN & CO. LTD

4. Full name of shareholder(s)  (if different from 3.):iv

J. M. FINN NOMINEES LTD

 

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

12th February 2013

6. Date on which issuer notified:

13th February 2013

7. Threshold(s) that is/are crossed orreached: vi, vii

5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GBP 0.1 ISIN:

GB0001646941

5895423

 

5895423

 

5895423

 

5895423

 

4.78%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

5895423

 

4.78%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

15. Contact telephone number:

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLGGUQAPUPWGWA
Date   Source Headline
7th Jul 20227:00 amRNSExercise of Options
29th Jun 202212:18 pmRNSResult of AGM
29th Jun 20227:00 amRNSAGM Statement
8th Jun 20227:12 amRNSNotice of AGM & Publication of Annual Report
7th Jun 20227:00 amRNSInvestor Meet Company: 2021 Results Presentation
31st May 202210:29 amRNSDirector/PDMR Shareholding
31st May 20227:00 amRNSPreliminary results
16th May 20225:05 pmRNSHolding(s) in Company
10th May 20227:00 amRNSRegulatory update
2nd Mar 20227:00 amRNSTrading Update
2nd Dec 20217:00 amRNSNew Major Crop Use for Mevalone in France
20th Oct 20217:00 amRNSAdmission to the US OTC Market
28th Sep 20217:00 amRNSHalf Yearly Report
24th Sep 202112:32 pmRNSNotice of General Meeting
1st Sep 20217:00 amRNSIssuing of Annual Report & Notice of GM
26th Aug 20217:00 amRNSNew label extension for biofungicide in Portugal
28th Jul 20212:53 pmRNSDirector/PDMR Shareholding
27th Jul 20217:00 amRNSAgreement with Sipcam in North Africa
23rd Jul 20217:00 amRNSGrant of Awards under Long-Term Incentive Plan
12th Jul 20214:10 pmRNSHolding(s) in Company
5th Jul 20217:00 amRNSRegulatory approvals
1st Jul 202112:19 pmRNSPublication of Report and Accounts
30th Jun 202112:03 pmRNSResult of AGM
30th Jun 20217:00 amRNSPreliminary Results for Year Ended 31 Dec 2020
29th Jun 202111:27 amRNSVirtual Investor Conference – Link for webinar
7th Jun 20213:28 pmRNSNotice of AGM, investor conference & Accounts
12th May 20217:00 amRNSMilestone Agreement signed with Corteva
10th May 20217:00 amRNSRegulatory approval for Cedroz™ in Italy
1st Apr 20217:00 amRNSGrant of Awards under Long-Term Incentive Plan
31st Mar 20217:00 amRNSNew authorisations for bio-fungicide in Spain
29th Mar 20211:27 pmRNSHolding(s) in Company
19th Feb 20214:41 pmRNSSecond Price Monitoring Extn
19th Feb 20214:35 pmRNSPrice Monitoring Extension
19th Feb 20212:05 pmRNSSecond Price Monitoring Extn
19th Feb 20212:01 pmRNSPrice Monitoring Extension
11th Feb 20219:05 amRNSSecond Price Monitoring Extn
11th Feb 20219:00 amRNSPrice Monitoring Extension
11th Feb 20217:00 amRNSYear end trading update
5th Jan 20217:00 amRNSGreen Economy Mark
2nd Nov 20207:00 amRNSEden partners with M H Poskitt
13th Oct 20207:00 amRNSChange of Registered Office
29th Sep 20207:00 amRNSHalf-year Report
17th Sep 20207:00 amRNSNew authorisations for Cedroz™ and Mevalone®
15th Sep 20207:00 amRNSKey patent granted for Eden’s Sustaine technology
1st Sep 20207:00 amRNSRegulatory approval for Cedroz™ in Spain
25th Aug 20207:00 amRNSNew authorisation for bio-fungicide in Australia
5th Aug 20207:00 amRNSNew authorisation for Cedroz™ in Greece
10th Jul 20207:00 amRNSAppointment of Global Head of Biology and Dev
1st Jul 20207:00 amRNSNew office and laboratory in Oxfordshire
25th Jun 20207:00 amRNSPatents granted in the United States

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.